Q3 2026 Charles River Laboratories International, Inc. Earnings Conference Call - CHARLES RIVER LABORATORIES INTERNATIONAL INC

Explicit Guidance:

• Full Year 2026 Revenue: Raising reported revenue outlook to a decline of 1.5% to 2.0%; raising organic revenue growth guidance to >1.5% (previously 1-3%); narrowing guidance by segment (DSA >2%, Manufacturing mid-single-digit, RMS low-single-digit decline).
• Full Year 2026 Earnings: Increasing non-GAAP EPS guidance by $0.15 to a range of $11.35 to $12.55 (midpoint $11.95), representing 10-12% YoY growth; full-year non-GAAP operating margin expansion expected at 120-150 basis points.
• Full Year 2026 Tax Rate: Expected non-GAAP tax rate of approximately 23% (lower end of prior range) due to favorable foreign tax legislation impacts.
• Full Year 2026 Interest Expense: Net interest expense expected at the upper end of the previous range of $103–$108 million due to higher interest rates.
• Full Year 2026 CapEx: Unchanged at approximately $200 million (~5% of revenue), aligned with long-term targets of 5-6%.
• Full Year 2026 Free Cash Flow: Unchanged guidance of $400–$420 million.
• Q4 2026 Outlook: Embedded in full-year guidance; expects DSA organic growth in mid-single digits, Manufacturing in high single digits, and modest RMS growth reduction; expects non-GAAP EPS growth of 30-40% YoY driven by margin expansion and lower sourcing costs.
• 2027 Outlook (Qualitative): Expect gradual improvement in organic growth from 2026 levels; revenue growth targeting 5-7% range starting 2028.
• 2027 Margin Outlook: Expects operating margin improvement in 2027 to exceed the 75 basis point annualized target seen through 2030, driven by full-year impact of 2026 divestitures/acquisitions and $300 million in cost savings from the "Create the Future" program.

Business-Segment Outlook:

• DSA (Drug Safety Assessment): Targets long-term organic growth of 5-7%; Q3 DSA net book-to-bill was 1.09x (4th consecutive quarter >1.0x), averaging ~1.1x over the trailing 12 months, supporting long-term targets; expects continued mid-single-digit organic growth in Q4 2026; anticipates pricing power benefits (covering inflation) beginning in the second half of 2027 due to lag times in backlog execution.
• Manufacturing: Rebounded to 7.4% organic growth in Q3; expects to approach 40% operating margin by year-end 2026 (up from 38.6% in Q3); expects mid-single-digit organic growth for the year; key growth drivers include microbial solutions and biologics testing; expects continued sequential margin improvement in Q4.
• RMS (Research Models & Services): Expected low-single-digit organic decline for 2026; margin expected to be modestly lower sequentially in Q4 due to seasonality; trends driven by strong double-digit growth in China offset by softer demand in North America (academic/government); full re-acceleration expected to take longer than DSA/Manufacturing due to 40% revenue exposure to academic/government clients.

Market and Competitive Outlook:

• Demand Trends: Biopharmaceutical demand environment remains positive with "improving momentum"; large pharma clients are reinvesting in R&D pipelines post-restructuring; biotech funding remains robust at ~$100 billion (trailing 12-month) despite Q3 slowdown; DSA proposal activity and capture rates remain strong (5th consecutive quarter of YoY proposal growth).
• Pricing Dynamics: Currently modestly reducing discount levels in proposals to cover cost inflation; pricing power not yet realized in revenue (lagging indicator); full pricing impact expected in H2 2027; no immediate benefit anticipated from pricing in Q4 2026.
• Competitive Positioning: Strong competitive advantage in non-human primate (NHP) supply (own ~80% of estimated usage via internal farms); expanding global footprint; "Pathway to Purpose" strategy aimed at increasing share of R&D spend via client-centricity and scientific leadership.
• AI Impact: Viewing AI as a long-term tailwind increasing the number of programs reaching IND-enabling stages; expecting "AI-native" companies to run more validation programs (shots on goal) to prove platforms; no immediate disruption to volumes or dollar-per-program value for CROs.

Macro / Industry Outlook:

• Macroeconomics: Monitoring inflation, oil prices, interest rates, and biotech funding; no current signs of disruption to demand trends; views market environment as "healthy" despite pockets of softness in early-stage biotech and academic funding.
• Regulatory/Tariffs: Mentioned "OB-3" bill and global minimum tax provisions affecting prior year tax rate; expecting favorable impact of tax legislation changes in foreign jurisdictions for current year; collaborating with FDA on preclinical screening tools and virtual control groups (VCGs).
• Industry Structural Changes: Transitioning from "one-off" projects to "AI-native" drug discovery requiring higher volumes of validation studies; shift toward complex modalities (biologics, ADCs, mRNA) driving demand for advanced testing capabilities.

Strategic Initiatives:

• "Create the Future" Transformation: Modernization program expected to generate $300 million in cumulative cost savings over the next four years; key driver for margin improvement in 2027 and beyond.
• Specific Modernization Examples: July 2026 launch of fully automated manufacturing suite for EndoSafe technology (increased cartridge production capacity by 14%); partnership with Autolimus to launch "Apollo Orchestrate" to digitize lab workflows.
• Scientific Capability Expansion: Collaboration with FDA to validate preclinical screening tools for drug abuse potential; launch of rapid cell banking program (reducing cell bank production timelines by 40% vs 20-week industry standard); adoption of Virtual Control Groups (VCGs) for regulatory submission (e.g., Ipsen study).
• Capacity: Comfortable with current in vivo capacity for next two years; actively expanding bioanalytical capacity via five ongoing organic expansions; disciplined approach to capital expenditure with room to convert existing space quickly if needed.
• M&A/Divestitures: CDMO business divested (fully integrated in results); exploring potential M&A in bioanalytical space; 500 modernization initiatives ongoing.

Risks and Headwinds to Outlook:

• Pricing Lag: Full realization of pricing power to cover inflation delayed until H2 2027; current pricing trends may not immediately benefit DSA revenue.
• RMS Headwinds: Slowdown in academic/government funding and North American small model volumes continuing to pressure RMS; re-acceleration expected to take longer than other segments.
• Supply Chain: Potential tightness in NHP supply in China (cannot export for own studies); monitoring market pricing and availability; currently covered ~80% of usage via own farms but watching external demand.
• Macro Sensitivity: Monitoring biotech funding trends and macroeconomic variables (inflation, rates) for potential disruption; pockets of unimproved demand in early-stage biotech and startup formation.
• Execution Risk: "Create the Future" savings and margin targets depend on successful execution of cost initiatives and timing of backlog absorption.

Management Tone on the Future:

• Confidence Level: Cautiously optimistic ("encouraged," "solid," "favorable"); strong confidence in the return of growth and margin expansion; belief in the "Pathway to Purpose" strategy.
• Guidance Changes: Upgraded full-year revenue and EPS guidance based on Q3 outperformance; narrowed segment guidance ranges to reflect clearer trends; maintaining long-term 5-7% growth target for 2028+.
• Strategic Narrative: Emphasis on "simplifying the company," "moving faster," and "investing where we can win"; focus on operational excellence and scientific leadership to drive shareholder value.

Miscellaneous:

• Virtual Control Groups (VCGs): Moving from concept to regulatory submission; expected to be paid alongside regular control groups (no immediate revenue upside, but strategic/ethical value); significant milestone for reducing animal use.
• Non-Human Primate (NHP) Strategy: Internalizing supply chain to control quality and cost; selling excess NHPs in China through RMS; seeing increased demand for NHP studies due to complex biologics pipelines.
• Investor Relations: Full-year 2027 guidance to be provided at Q4 earnings in February; webcast replay available on ir.criver.com.